Hi there @dyode,
you’re a thoughtful person.
Looking at the risk of improper -blast formation during CLBP treatment generally, any thoughts on FDA’s likely view of the perceived need for actual trilineage differentiation in vivo (cf. differentiability) for Revascor (an MPC) to be considered and characterised as potent?
Personally, I don’t think it’s important when an MoA signalling cascade requires MPC apoptosis. Idle thought.
Cheers
Hi there @dyode,you’re a thoughtful person. Looking at the risk...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |